In a similar strategy to the MG1-MAGEA3 + AdMA3 tumor vaccination approach, tumors are first primed with replication-incompetent Ad expressing HPV E6 and E7 (AdE6E7), followed by the administration of oncolytic MG1-E6E7 and the anti-PD-L1 inhibitor atezolizumab in patients with advanced or recurrent HPV-associated tumors (NCT03618953). This evidence concerns the gene MUC5B and neoplasm.